Effect Of Dexmedetomidine On Sublingual Microcirculation In Patients Undergoing On Pump CABG Surgery

January 23, 2018 updated by: Hassan mohamed, Cairo University

Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery

This study is designed to explore the possible effects of dexmedetomidine infusion on sublingual microcirculation in patients undergoing on-pump coronary artery bypass graft surgery

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

All patients will be premedicated the night before surgery with bromazepam 3 mg PO, and 0.1 mg/Kg morphine sulphate IM one hour preoperatively. Upon arrival to the pre-induction room, the patient will receive supplementary oxygen via a nasal cannula, and will be monitored with ECG, Non invasive blood pressure and pulse oximeter. Under local infiltration anesthesia (lidocaine 2%) a peripheral venous cannula (14 or 16 G) and a 20 G arterial cannula will be inserted. Induction of anesthesia will be accomplished with fentanyl (7-10 μg/Kg), propofol 0.5 - 1.0 mg/Kg and pancuronium (0.08 - 0.12 mg/Kg). After intubation a triple lumen central venous catheter will be inserted in a central vein. The temperature probe will be inserted in the nasopharynx; the TEE probe will be also inserted after decompression of the stomach with a nasogastric tube.

All patients will be mechanically ventilated with a tidal volume of 6-8 mL/kg and a respiratory rate of 12 - 14 to achieve end-tidal CO2 30 - 35 mmHg . A PEEP of 5 cm H2O is also added. FiO2 will be adjusted to achieve a PaO2 between 200 and 300 mmHg. Isoflurane will be adjusted to 1 - 1.5 expired MAC , as well as fentanyl increments of 2 μg/Kg will be used to control adequate level of anesthesia and to maintain hemodynamic stability. Incremental doses of pancuronium will be administered as needed.

Before starting CPB anticoagulation with 400IU/kg heparin iv will be administered and activated clotting time (ACT) will be used to check proper anticoagulation throughout CPB aiming at ACT >400s.

Cardiopulmonary bypass flow rate of 2.2 - 2.4 l/min/m2 is maintained aiming to keep MAP of 50-80 mmHg together with the use of vasopressors and vasodilators when needed. After Initiation of CPB mild hypothermia (34-35℃) will be performed . During weaning from CPB, volume and pharmacological therapy with inotropes and vasodilators will be used as needed to maintain hemodynamic stability. All blood on the CPB machine will be re-infused into the patient and protamine will be administered in a dose of 4 mg/kg to return ACT to baseline values.

Using a computer-generated random sequence of numbers, patients will be allocated to one of the following two study groups:

- Control group (Group C): During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion

- Group Dexmedetomidine (Group DEX): During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr Patients and investigators performing the study and assessing its outcomes will all be blinded to the study group allocation. The study drugs will be prepared by a separate investigator not involved in either study performance or analysis.

Data collection Microcirculation will be studied with side-stream dark field (SDF) imaging (Microscan; MicroVision Medical, Amsterdam, Netherlands) at three times; Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass (T2) Side stream dark field imaging is equipped with sterile caps to avoid contamination. Briefly, after gentle cleansing by isotonic-saline-drenched gauze, avoiding pressure artefacts, 5 steady images of at least 20 seconds each will be obtained and stored under a random number. Offline blind analysis of each video will be done by two investigators. A previously validated semiquantitative score will be used . It distinguishes between no flow (0), intermittent flow (1), sluggish flow (2), and continuous flow (3). A value is assigned to each individual vessel. The overall score, called the microvascular flow index (MFI), is the average of the individual values. For each patient, the values from 5 videos will be averaged. In addition, vascular density will be quantified as the number of vessels per millimeters squared. To determine heterogeneity of perfusion, the flow heterogeneity index will be calculated as the highest MFI minus the lowest MFI divided by the mean MFI. Finally, the percent of perfused vessels and the total and capillary perfused vascular densities will be calculated. The percent of perfused vessels will be calculated as the number of vessels with flows 2 and 3 divided by the total number of vessels and multiplied by 100. The perfused vascular density will be calculated as the number of vessels multiplied by the fraction of perfused vessels. These quantifications of flow were made per group of vessel diameter: small (capillaries), 10 to 20 μm; medium, 21 to 50 μm; and large, 51 to 100 μm Sample size (number of participants included) 68 patients (34 in each group) Power analysis was performed using Student's t-test for independent samples with MFI as the primary outcome. A previous study demonstrated that MFI during cardiopulmonary bypass was approximately 2.6 + 1. Sample size was calculated to detect a 25% difference in MFI between the two groups with a power of 0.8 and an alpha error of 0.5. A minimum of 62 patients (31 in each group) would be necessary, and this was increased to 68 (34 in each group) to compensate for dropouts.

Statistical analysis Data will expressed as mean + SD, median (range), or frequency as appropriate. Categorical variables will be compared using Chi-square or Fisher's exact test as appropriate. Normally distributed data will be compared using Student's t-test while non-normally distributed data will be compared using Mann-Whitney test or the Kruskal-Wallis test as appropriate. Intergroup comparisons will be done using analysis of variance with repeated measures and post-hoc Dunnett test. A P-value < 0.05 will be considered statistically significant.

Study Type

Interventional

Enrollment (Anticipated)

70

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
      • Cairo, Egypt, 11562
        • Recruiting
        • Kasr Al-Ainy hospitals , Faculty of medicine , Cairo university
        • Contact:
        • Principal Investigator:
          • Hossam S El-Ashmawi, MD
        • Sub-Investigator:
          • Hassan M Hassan, MD., FCAI
        • Sub-Investigator:
          • Hisham H Abdel Wahab, MD
        • Sub-Investigator:
          • Pierre Z Tawadros, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients aged (>18), males and females, undergoing elective coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).

Exclusion Criteria:

  • Patient refusal.
  • Emergency surgeries
  • Redo surgeries
  • Pregnancy
  • Vasculitis
  • Inflammation or infection at the study site
  • History of allergic reaction to study medications

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group (Group C)
During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
Drug: Placebo for Dexmedetomidine normal saline infusion
During bypass, patients will receive normal saline infusion
Other Names:
  • Normal saline infusion
Drug: Propofol infusion
During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Other Names:
  • Diprivan
Active Comparator: Group Dexmedetomidine (Group DEX)
During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
Drug: Propofol infusion
During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
Other Names:
  • Diprivan
Drug: Dexmedetomidine
During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
Other Names:
  • Precedex

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Microvascular flow index
Time Frame: Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Microcirculation will be studied with side-stream dark field (SDF) imaging (Microscan; MicroVision Medical, Amsterdam, Netherlands) 5 steady images of at least 20 seconds each will be obtained and stored under a random number. Offline blind analysis of each video will be done by two investigators. A previously validated semiquantitative score will be used (15). It distinguishes between no flow (0), intermittent flow (1), sluggish flow (2), and continuous flow (3). A value is assigned to each individual vessel. The overall score, called the microvascular flow index (MFI), is the average of the individual values.
Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Total vascular density
Time Frame: Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
the number of vessels per millimeters squared
Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Change in perfused vessel density
Time Frame: Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
the number of vessels multiplied by the fraction of perfused vessels
Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Change in proportion of perfused vessel
Time Frame: Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
the number of vessels with flows 2 and 3 divided by the total number of vessels and multiplied by 100
Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Change in Serum lactate
Time Frame: Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Immediately before starting CBP (T0) , 30 min after initiation of bypass (T1), and 30 min after weaning from bypass
Hemodynamic parameters
Time Frame: Every hour for six hours after induction
Mean arterial pressure (MAP)
Every hour for six hours after induction
Vasopressor dose
Time Frame: Every hour for six hours after induction
Every hour for six hours after induction

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Study Chair: Hisham H Abdel Wahab, MD, Cairo University
  • Principal Investigator: Hossam S El-Ashmawi, MD, Cairo University
  • Study Chair: Pierre Z Tawadros, MD, Cairo University
  • Study Director: Hassan M Hassan, M.D,FCAI, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Anticipated)

May 1, 2018

Study Completion (Anticipated)

August 1, 2018

Study Registration Dates

First Submitted

March 13, 2016

First Submitted That Met QC Criteria

March 16, 2016

First Posted (Estimate)

March 21, 2016

Study Record Updates

Last Update Posted (Actual)

January 24, 2018

Last Update Submitted That Met QC Criteria

January 23, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N-54-2015

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sublingual Microcirculation

Clinical Trials on Placebo for Dexmedetomidine normal saline infusion

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe